Skip to content

News

4

March 4, 2021

In Latest NewsPosted March 4, 2021

ALX Oncology and Tallac Therapeutics Announce Collaboration on Novel Class of Cancer Immunotherapeutics

Categories

Latest News (6)

Search for:

Recent Posts

Tallac Therapeutics Appoints Curtis Hecht as Chief Business Officer
Tallac AACR 2021 Presentation
AACR 2021 presentation on preclinical data for TAC-001
ALX Oncology and Tallac Therapeutics Announce Collaboration on Novel Class of Cancer Immunotherapeutics
Tallac Therapeutics Launches with $62 Million in Series A Financing to Advance Novel Immunotherapies for Cancer

Archives

April 2021
March 2021
December 2020
November 2020

(650) 866-1966

866 Malcolm Road Suite 100, Burlingame, CA 94010

Copyright © 2020 Tallac Therapeutics, Inc. All Rights Reserved.